Skip to main content

Table 2 Factors associated with OS in all patients diagnosed with stage IIIB–IV NSCLC in 2012–2016

From: Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

Parameter Patients, n (%) Factors associated with OSa
N = 1008 HR (95% CI) P value
Age at NSCLC diagnosis in years    <  0.001
  < 65 478 (47.4) 1.00 (ref)
 65–74 307 (30.5) 1.12 (0.96–1.32)
  ≥ 75 223 (22.1) 1.50 (1.26–1.79)
Sex    0.045
 Male 762 (75.6) 1.00 (ref)
 Female 246 (24.4) 0.83 (0.70–0.996)
TNM stage and brain metastasis at diagnosis    <  0.001
 Stage IIIB 154 (15.3) 1.00 (ref)
 Stage IV without brain metastasis 691 (68.6) 1.56 (1.26–1.94)
 Stage IV with brain metastasis 163 (16.2) 2.92 (2.25–3.79)
Histology and mutations/rearrangement    <  0.001
 NSQ 720 (71.4)
 NSQ EGFR and ALK wildtype 476 (47.2) 1.00 (ref)
 NSQ EGFR or ALK mutations/rearrangements 142 (14.1) 0.49 (0.38–0.63)
 NSQ EGFR/ALK not tested 102 (10.1) 1.57 (1.25–1.98)
 SQ 210 (20.8) 1.14 (0.95–1.38)
 NSCLC NOS/Others 78 (7.7) 1.43 (1.11–1.84)
  1. OS overall survival, NSCLC non-small cell lung cancer, HR hazard ratio, CI confidence interval, ref reference category, TNM tumour, node, and metastasis, NSQ non-squamous cell carcinoma, EGFR epidermal growth factor receptor gene, ALK anaplastic lymphoma kinase gene, SQ squamous cell carcinoma, NOS not otherwise specified
  2. a Multivariate Cox model; survival within 2 years of diagnosis; an HR < 1 indicates better OS than the reference and an HR > 1 indicates a worse OS than the reference